TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28371488

Group type: EXPERIMENTAL
Intervention: Innovative film‐coated warfarin sodium tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Marketed sugar‐coated warfarin sodium tablets
Number of subjects: 24
Study: 27397586

Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 74
Study: 24094827

Group type: EXPERIMENTAL
Intervention: Recovery with normo-glycemia after hypoglycemia
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Recovery with hyperglycemia after hypoglycemia
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Recovery with hyperglycemia after hypoglycemia with vitamin C infusion
Number of subjects: 43
Study: 21968280

Group type: EXPERIMENTAL
Intervention: Relaxation training program (mini mp3 player with 13-min relaxation audio program, followed daily)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Routine prenatal care (control group)
Number of subjects: 127
Study: 20089825

Group type: EXPERIMENTAL
Intervention: Generic clozapine (Gen-Clozapine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clozaril
Number of subjects: 0
Study: 18232722

Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 325
Study: 16805928

Group type: EXPERIMENTAL
Intervention: Live interactive music
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pre-recorded music
Number of subjects: 32

Group type: COMPARATOR
Intervention: Silence (placebo)
Number of subjects: 32
Study: 14762496

Group type: EXPERIMENTAL
Intervention: Midazolam (1.0 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Midazolam (0.75 mg/kg) plus Hydroxyzine (2.0 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10800814

Group type: EXPERIMENTAL
Intervention: Vivostat fibrin sealant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 30
Study: 8846278

Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous Morphine Infusion (CMI)
Number of subjects: 30
Study: 1999715

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy during chemotherapy administration
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no cryotherapy)
Number of subjects: 95
Study: 6542398

Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Praziquantel 25 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Praziquantel 15 mg/kg
Number of subjects: 72
Study: 30682128

Group type: EXPERIMENTAL
Intervention: Reading abstracts with overstatement
Number of subjects: 567

Group type: COMPARATOR
Intervention: Reading abstracts without overstatement
Number of subjects: 567
Study: 29703606

Group type: EXPERIMENTAL
Intervention: Panitumumab with Best Supportive Care (BSC)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 270
Study: 26968520

Group type: EXPERIMENTAL
Intervention: Complex, multifaceted intervention including healthcare professional education, local concertation, and interdisciplinary case conferences.
Number of subjects: 2205

Group type: COMPARATOR
Intervention: Control group (usual care).
Number of subjects: 2205
Study: 24945286

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (808 nm laser irradiation as 4 J/point for 20 s over ipsilateral three nerve roots and 0.1 J/cm2 for 5 min in tangential scanning mode)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (lidocaine-only)
Number of subjects: 48
Study: 22737868

Group type: EXPERIMENTAL
Intervention: Sanchi Tong Shu capsule
Number of subjects: 206

Group type: COMPARATOR
Intervention: Betahistine mesilate tablets
Number of subjects: 206
Study: 21195985

Group type: EXPERIMENTAL
Intervention: CO(2) insufflation under deep sedation
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Air insufflation under deep sedation
Number of subjects: 104

Group type: COMPARATOR
Intervention: CO(2) insufflation under conscious-sedation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Air insufflation under conscious-sedation
Number of subjects: 104

Group type: COMPARATOR
Intervention: CO(2) insufflation under awake
Number of subjects: 104

Group type: COMPARATOR
Intervention: Air insufflation under awake
Number of subjects: 104
Study: 17435545

Group type: EXPERIMENTAL
Intervention: Mental training
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Practical training
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 98
Study: 16050412

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elemental calcium (max 1000 to 1500 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferric citrate, colestilan, and nicotinamide
Number of subjects: 0
Study: 12813472

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 10392964

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine (clinical trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine (matched controls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine (matched to tacrolimus group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine (matched to cyclosporine group)
Number of subjects: 0
Study: 8699054

Group type: EXPERIMENTAL
Intervention: Three doses of RRV‐TV vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One dose of RRV‐TV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One and three doses of RRV‐TV vaccine
Number of subjects: 0
Study: 2021564

Group type: EXPERIMENTAL
Intervention: Self-help manual for smoking cessation
Number of subjects: 745

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 745
Study: 7044294

Group type: EXPERIMENTAL
Intervention: 100 mg of amantadine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 100 mg of rimantadine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 4 mg of chlorpheniramine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 100 mg of amantadine + 4 mg of chlorpheniramine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30941562

Group type: EXPERIMENTAL
Intervention: Leuprolide mesylate subcutaneous injectable suspension (LMIS) 50 mg
Number of subjects: 137
Study: 31829173

Group type: EXPERIMENTAL
Intervention: Guanxinshutong (GXST) capsules
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 29609146

Group type: EXPERIMENTAL
Intervention: Group psychotherapeutic intervention based on cognitive‐behavioral therapy (CBT); 8 weekly, semi‐structured group meetings.
Number of subjects: 47
Study: 27055643

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.03 mg/kg) and Atropine (0.01 mg/kg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Saline (0.1 ml/kg)
Number of subjects: 160
Study: 24138922

Group type: EXPERIMENTAL
Intervention: Amphetamine challenge in high-risk group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Amphetamine challenge in stimulant drug-naïve healthy control subjects
Number of subjects: 16

Group type: COMPARATOR
Intervention: Amphetamine challenge in subjects matched to high-risk group on personal drug use
Number of subjects: 16
Study: 22578529

Group type: EXPERIMENTAL
Intervention: Puerarin (1200 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19462315

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17468814

Group type: EXPERIMENTAL
Intervention: Sivelestat (neutrophil elastase inhibitor)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 16421344

Group type: EXPERIMENTAL
Intervention: High-dairy diet (HD) with acute energy deficit
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-dairy diet (LD) with acute energy deficit
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-dairy diet (HD) under energy balance
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-dairy diet (LD) under energy balance
Number of subjects: 19
Study: 11913291

Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide tooth-whitening gel strip, used for 30 minutes per day, twice daily for 2 months
Number of subjects: 0
Study: 9818805

Group type: EXPERIMENTAL
Intervention: 100-Hz electroacupuncture with needles inserted into the appropriate point in each ear
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham control procedure over the mastoid bone
Number of subjects: 76
Study: 7695301

Group type: EXPERIMENTAL
Intervention: DU-6859a 25 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DU-6859a 50 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DU-6859a 100 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DU-6859a 200 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DU-6859a 100 mg three times a day for 6 days plus once a day on the 7th day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DU-6859a 50 mg every 12 h for 13 doses
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DU-6859a (all doses)
Number of subjects: 36
Study: 2468957

Group type: EXPERIMENTAL
Intervention: isradipine 5-10 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 407914

Group type: EXPERIMENTAL
Intervention: Intraduodenal feeding of water, electrolytes, protein, and calories
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous (i.v.) feeding of amino acids and calories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastrointestinal tract feeding of protein and calories
Number of subjects: 0
Study: 30664548

Group type: EXPERIMENTAL
Intervention: Driving pressure-guided ventilation (n = 145): tidal volume 6 ml/kg of ideal body weight, individualized PEEP to minimize driving pressure.
Number of subjects: 292

Group type: COMPARATOR
Intervention: Conventional protective ventilation (n = 147): tidal volume 6 ml/kg of ideal body weight, PEEP 5 cm H2O, and recruitment maneuver.
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Driving pressure-guided ventilation (n = 145)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Conventional protective ventilation (n = 147)
Number of subjects: 292
Study: 27901287

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 100
Study: 25746399

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (51%-70% of predicted HR(max))
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sedentary behavior
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (volume of maximum oxygen consumption)
Number of subjects: 87
Study: 24010572

Group type: EXPERIMENTAL
Intervention: 80/480 mg tablet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 60/360 mg tablet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Four standard tablets
Number of subjects: 120

Group type: COMPARATOR
Intervention: Three standard tablets
Number of subjects: 120
Study: 21324142

Group type: EXPERIMENTAL
Intervention: Neoadjuvant imatinib (IM) treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Surgical resection after neoadjuvant IM
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Surgical resection followed by continuous IM treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Surgical resection followed by IM
Number of subjects: 25
Study: 18851855

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 0.6 g per day plus 17-hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo plus 17-hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 280
Study: 16966303

Group type: EXPERIMENTAL
Intervention: A. fumigatus challenge
Number of subjects: 27
Study: 15457023

Group type: EXPERIMENTAL
Intervention: Transthecal digital block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subcutaneous infiltration block
Number of subjects: 50
Study: 11726254

Group type: EXPERIMENTAL
Intervention: Training group (TRN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CTL)
Number of subjects: 20
Study: 9355081

Group type: EXPERIMENTAL
Intervention: Induction therapy with antilymphocyte antibodies
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional therapy (cyclosporine, azathioprine, and prednisone)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 7
Study: 8202978

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback treatment together with physical therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physical therapy only
Number of subjects: 16
Study: 3098555

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Phenobarbital (PB)
Number of subjects: 39
Study: 31743282

Group type: EXPERIMENTAL
Intervention: CGRP expression in blind, painful eyes (n=8)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (nonpainful enucleated eyes)
Number of subjects: 8
Study: 30845958

Group type: EXPERIMENTAL
Intervention: Multi-level intervention combining implementation science and community-based participatory research approaches; includes optimization of acute stroke care in emergency departments and community-wide workshops led by peer educators over 2 years.
Number of subjects: 0
Study: 27889390

Group type: EXPERIMENTAL
Intervention: 1000 mg GSE
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1500 mg GSE
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 2500 mg GSE
Number of subjects: 29
Study: 25214069

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg annually for up to three injections (years 4, 5, and 6)
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Placebo for 3 years (years 1, 2, and 3)
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 1223
Study: 23739813

Group type: COMPARATOR
Intervention: Low dose (0.00375 mmol/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Medium dose (0.0075 mmol/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High dose (0.0150 mmol/kg)
Number of subjects: 18
Study: 21524238

Group type: EXPERIMENTAL
Intervention: naproxen/esomeprazole magnesium
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: celecoxib
Number of subjects: 1234
Study: 18813412

Group type: EXPERIMENTAL
Intervention: Ginger capsules 3 g/day in 3 divided doses for 45 days
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (lactose capsule 3 g/day in 3 divided doses for 45 days)
Number of subjects: 85
Study: 17059329

Group type: EXPERIMENTAL
Intervention: RT-PCR using MMG marker
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: RT-PCR using CEA marker
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combination of MMG and CEA markers
Number of subjects: 59
Study: 15312092

Group type: EXPERIMENTAL
Intervention: Machined surface implants
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rough-surface Tioblast implants
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall failure rate
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Radiographic signs of loss of osseointegration
Number of subjects: 51
Study: 11269585

Group type: EXPERIMENTAL
Intervention: Preconditioned patellar tendon autograft (group P)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No preconditioning (group NP)
Number of subjects: 53
Study: 9313757

Group type: EXPERIMENTAL
Intervention: High-dose intravenous insulin infusion (1.2 +/- 0.4 U.kg‐1.day‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intensive insulin therapy (0.4 +/- 0.1 U.kg‐1.day‐1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-dose intravenous insulin infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intensive insulin therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-dose intravenous insulin infusion and Intensive insulin therapy
Number of subjects: 19
Study: 8337206

Group type: EXPERIMENTAL
Intervention: Self-monitoring of diet
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Self-monitoring of exercise
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Self-monitoring of aerobic physical activity
Number of subjects: 314
Study: 3780088

Group type: EXPERIMENTAL
Intervention: Intraarticular methylprednisolone (40 mg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 30048006

Group type: EXPERIMENTAL
Intervention: 2 repeated intrathecal injections of autologous bone marrow–derived mesenchymal stem cells (BM‐MSCs)
Number of subjects: 64

Group type: COMPARATOR
Intervention: riluzole alone
Number of subjects: 64
Study: 27797708

Group type: EXPERIMENTAL
Intervention: Hesperidin 2S (450 mg/d)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 24325594

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT) program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional non‐structured therapy program (control group)
Number of subjects: 30
Study: 22890117

Group type: COMPARATOR
Intervention: S(+)‐ketamine (20 mg/70 kg for the first hour, 40 mg/70 kg for the second hour)
Number of subjects: 12

Group type: COMPARATOR
Intervention: S(+)‐ketamine
Number of subjects: 12
Study: 19880291

Group type: EXPERIMENTAL
Intervention: Olive oil-based lipid emulsion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Long-chain triacylglycerols
Number of subjects: 36

Group type: COMPARATOR
Intervention: Medium-chain/long-chain triacylglycerols
Number of subjects: 36
Study: 17912634

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 16212446

Group type: EXPERIMENTAL
Intervention: clinic-directed group, replicating the parameters of the early intensive behavioral treatment developed at UCLA
Number of subjects: 24

Group type: COMPARATOR
Intervention: parent-directed group that received intensive hours but less supervision
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: combined groups
Number of subjects: 24
Study: 12070712

Group type: EXPERIMENTAL
Intervention: GM-CSF/IL-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 20
Study: 10951234

Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid plus red light
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Light alone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 22
Study: 8828743

Group type: EXPERIMENTAL
Intervention: HIV RNA levels
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: CD4 count
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: HIV RNA levels and CD4 count (multiple regression model)
Number of subjects: 620
Study: 1446477

Group type: EXPERIMENTAL
Intervention: Increased inhaled corticosteroid (mean 1478 micrograms daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Regular inhaled bronchodilator (on-demand beta-agonist)
Number of subjects: 32
Study: 3913273

Group type: EXPERIMENTAL
Intervention: 0.25% timolol maleate (Blocanol)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate (Blocanol)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 0.25% timolol maleate (Oftan‐Timolol)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate (Oftan‐Timolol)
Number of subjects: 57
Study: 31601479

Group type: EXPERIMENTAL
Intervention: Immediate exercise (IE, during taxane chemotherapy)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Delayed exercise (DE, after chemotherapy)
Number of subjects: 27
Study: 28677088

Group type: EXPERIMENTAL
Intervention: Technical assistance providers rated their collaborative relationship with their teams
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Community readiness
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Team differences in change during the implementation phase
Number of subjects: 14
Study: 27391951

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1856

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1856

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 1856
Study: 24767613

Group type: EXPERIMENTAL
Intervention: Uncued walking (elderly)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Regularly cued walking (young)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Irregularly cued walking (young)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Regularly cued walking (higher executive function)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Walking conditions (lower executive function)
Number of subjects: 41
Study: 22698825

Group type: EXPERIMENTAL
Intervention: MRSA positive patients
Number of subjects: 190

Group type: COMPARATOR
Intervention: Non-MRSA patients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Abscess size ≥ 5 cm
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Abscess size < 5 cm
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Cellulitis size ≥ 5 cm
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Cellulitis size < 5 cm
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Larger abscesses
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Smaller abscesses
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Larger cellulitis
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Smaller cellulitis
Number of subjects: 190
Study: 20545916

Group type: EXPERIMENTAL
Intervention: PLACE HIV prevention intervention
Number of subjects: 2859

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2859
Study: 18568885

Group type: EXPERIMENTAL
Intervention: Topical ketorolac
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral ketorolac
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 32